BAXTER INTERNATIONAL INC Form PRE 14A

March 14, 2016

Table of Contents

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 14A

| | tursuant to Section 14(a) of the Secu 934 (Amendment No.) | rities |
|--|---|---|
| Filed by the Regist Filed by a Party ot | trant [X] her than the Registrant [] | |
| Check the appropr | iate box: | |
| [X] | Preliminary Pro Confidential, fo | xy Statement or Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| [] | Definitive Proxy | Statement |
| [] | Definitive Addit | tional Materials |
| [] | Soliciting Mater | rial Pursuant to §240.14a-12 |
| Baxter Intern (Name of Reg | national Inc. istrant as Specified In Its Charter) | |
| | (Name of Person(s | s) Filing Proxy Statement, if other than the Registrant) |
| Payment of Filing [X] [] | Fee (Check the appropriate box): No fee required. Fee computed on table below | per Exchange Act Rules 14a-6(i)(1) and 0-11. |
| | 1) | Title of each class of securities to which transaction applies: |
| | 2) | Aggregate number of securities to which transaction applies: |
| | 3) | Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): |
| | 4) | Proposed maximum aggregate value of transaction: |
| | 5) | Total fee paid: |
| [] | Fee paid previously with pre | liminary materials. |
| [] | | fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which reviously. Identify the previous filing by registration statement number, or the Form or |

Schedule and the date of its filing.

| 1) | Amount Previously Paid: |
|----|---|
| 2) | Form, Schedule or Registration Statement No.: |
| 3) | Filing Party: |
| 4) | Date Filed: |
| | |

Table of Contents

| May 3, 2016 Baxter International Inc. Headquarters One Baxter Parkway Deerfield, Illinois 60015 | Notice of 2016 Annual Meeting of Stockholders and Proxy Statement | |
|---|---|---|
| | | Baxter International Inc. Headquarters One Baxter Parkway |
| | | |
| | | |
| | | |

| Table of Contents | |
|---|--------------|
| | |
| | |
| | |
| Baxter International Inc. One Baxter Parkway | |
| Deerfield, Illinois 60015 | March , 2016 |
| Dear Stockholder: You are invited to attend Baxter s Annual Meeting of Stockholder our corporate headquarters located at One Baxter Parkway, Deer | |
| Details of the business to be conducted at the Annual Meeting are Stockholders and Proxy Statement. If you plan to attend the Annu on page 72 of the Proxy Statement. | <u> </u> |

In accordance with Securities and Exchange Commission rules, Baxter has elected to deliver its proxy materials over the Internet to most stockholders, which allows stockholders to receive information on a more timely basis, while lowering the company s printing and mailing costs and reducing the environmental impact of the Annual Meeting.

Your vote is very important. Whether or not you plan to attend in person, I urge you to vote your shares as promptly as possible. You may vote your shares by Internet or by telephone. If you received a paper copy of the proxy card by mail, you may sign, date and return the proxy card in the enclosed envelope. If you attend the Annual Meeting, you may revoke your proxy and vote in person.

Very truly yours,

José E. Almeida Chairman of the Board and Chief Executive Officer

9

Table of Contents

| Notice of 2016 Annual Meeting of Stockholders and Proxy Statement | <u>1</u> |
|--|-----------|
| Table of Contents | <u>2</u> |
| Notice of Annual Meeting of Stockholders | <u>3</u> |
| Proxy Statement Highlights | 4 |
| Corporate Governance at Baxter International Inc. | <u>9</u> |
| Proposal 1 Election Of Directors | <u>9</u> |
| Directors Continuing In Office | <u>12</u> |
| Board Of Directors | <u>16</u> |
| Other Corporate Governance Information | <u>19</u> |
| Board Responsibilities | <u>19</u> |
| Board Structure And Processes | <u>20</u> |
| Committees Of The Board | <u>21</u> |
| Director Compensation | <u>23</u> |
| Executive Compensation | <u>26</u> |
| Proposal 2 Advisory Vote to Approve Named Executive Officer Compensation | <u>26</u> |
| Compensation Committee Report | <u>27</u> |
| Compensation Discussion And Analysis | <u>27</u> |
| Executive Compensation Tables | <u>44</u> |
| Audit Matters | <u>59</u> |
| Proposal 3 Ratification Of Independent Registered Public Accounting Firm | <u>59</u> |

| Audit Committee Report | <u>60</u> |
|---|-----------|
| Audit And Non-Audit Fees | <u>61</u> |
| Pre-Approval Of Audit And Permissible Non-Audit Services | <u>61</u> |
| Proposed Charter Amendment | <u>62</u> |
| Proposal 4 Proposed Charter Amendment to Declassify Board | <u>62</u> |
| Ownership of our Stock | <u>64</u> |
| Security Ownership By Directors And Executive Officers | <u>64</u> |
| Security Ownership By Certain Beneficial Owners | <u>65</u> |
| Section16(a) Beneficial Ownership Reporting Compliance | <u>65</u> |
| Stockholder Proposals | <u>66</u> |
| Proposal 5 Independent Board Chairman | <u>66</u> |
| General Information | <u>69</u> |
| Questions And Answers About The Annual Meeting | <u>69</u> |
| Other Information | <u>72</u> |
| | |

^{| 2016} Annual Meeting of Stockholders and Proxy Statement

3

Notice of Annual Meeting of Stockholders

The 2016 Annual Meeting of Stockholders of Baxter International Inc. (the Annual Meeting) will be held at our corporate headquarters located at One Baxter Parkway, Deerfield, Illinois 60015, on Tuesday, May 3, 2016 at 9:00 a.m., Central Daylight Time, for the following purposes:

To elect the four directors named in the attached Proxy Statement. Subject to approval of Proposal 4 Proposed Charter Amendment to Declassify Board and the subsequent validation of the related amendment to Baxter s Certificate of Incorporation by the Delaware Court of Chancery (as described in such proposal), the specified directors will be elected to hold office for a term of one year. Otherwise elected directors will hold office for a term of three years.

- To approve named executive officer compensation for 2015.
- To ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for Baxter in 2016.
- To approve amendments to Baxter s Certificate of Incorporation to eliminate the classified board structure and provide for the annual election of directors.
- To vote on a stockholder proposal as described in the Proxy Statement, if such proposal is properly presented at the Annual Meeting.
- To transact any other business that may properly come before the meeting.

The Board of Directors recommends that stockholders vote FOR Items 1, 2, 3, and 4. The Board of Directors recommends that stockholders vote AGAINST the stockholder proposal referred to in Item 5. Stockholders of record at the close of business on March 9, 2016 will be entitled to vote at the meeting.

By order of the Board of Directors,

David P. Scharf Corporate Secretary

How Do I Vote?

By Internet, following the instructions on the Notice of Internet Availability of Proxy Materials or the proxy card;

By telephone, using the telephone number printed on the proxy card; or

By mail (if you received your proxy materials by mail), using the enclosed proxy card and return envelope.

Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting Of Stockholders to be Held On May 3, 2016

This Proxy Statement relating to the 2016 Annual Meeting of Stockholders and the Annual Report to Stockholders for the year ended December 31, 2015 are available at http://materials.proxyvote.com/071813.

Proxy Statement

The accompanying proxy is solicited on behalf of the Board of Directors for use at the Annual Meeting of Stockholders to be held on Tuesday, May 3, 2016. On or about March 24, 2016, Baxter began mailing to stockholders of record a Notice of Internet Availability of Proxy Materials providing instructions on how to access proxy materials via the Internet and how to vote online (www.proxyvote.com). Stockholders who did not receive the Notice of Internet Availability of Proxy Materials as a result of a previous election will receive a paper or electronic copy of the proxy materials, which Baxter also began sending on or about March 24, 2016.

investor.baxter.com



Proxy Statement Highlights

To assist you in reviewing the proposals to be acted upon at the Annual Meeting, this section presents concise detail about each non-routine voting item. For more complete information, please review our Annual Report on Form 10-K and the complete Proxy Statement.

PROPOSAL 1

Election Of Directors

What am I voting on?

You are asked to vote for the reelection of the four directors set forth below for a term of one year, subject to the approval of Proposal 4 Proposed Charter Amendment to Declassify Board and the subsequent validation of the charter amendment by the Delaware Court of Chancery. Otherwise, the directors will be elected for a three-year term.

What is the Board s recommendation?

The Board of Directors recommends a vote FOR the election of each of the director nominees.

The Board believes that the four directors standing for reelection possess a desirable mix of professional and industry experience and qualifications and have demonstrated an ability to effectively work together (along with other members of the Board) and constructively challenge each other and management. Additionally, they have overseen the execution of significant corporate governance developments at Baxter in 2015. See below for additional information regarding the qualifications, experiences and backgrounds of the Baxter board (including the director nominees) and recent Board developments.

Where can I find more information?

Concise supporting information is presented below.

See also Proposal 1 Election of Directors for additional information.

| Name | | Director | | Bax | cter (| Commi | ittees |
|--|-----------|---------------|---|-----|--------|-------|--------|
| Primary Occupation Thomas F. Chen (I) Senior Vice President and President of International Nutrition, About Laboratorica (retired) | Age 66 | Since 2012 | Key Attributes and Skills Extensive international business experience Global perspective | Α | С | CG | PP |
| Abbott Laboratories (retired) John D. Forsyth (I) Chairman and CEO, Wellmark Blue Cross Blue Shield | 68 | 2003 | Extensive experience in the healthcare industry Understanding of large, complex organizations | | | | |
| Michael F. Mahoney (I) President and CEO, Boston Scientific Corporation | 51 | 2015 | Significant knowledge of the global medical products business Extensive experience leading global, multi-faceted corporations | | | | |
| Carole J. Shapazian (I) Executive Vice President of Maytag Corporation (retired) | 72 | 2003 | Significant experience with, and insight into, global supply and service operations, manufacturing and distribution practices | | | | |
| Cov | | | | | | | |

Kev

| Rey | | | |
|--------------------------|-----------------------|--------------------------|-----------------------------------|
| (I) Independent director | Committee Chairperson | A Audit Committee | CG Corporate Governance Committee |
| | | C Compensation Committee | PP Public Policy Committee |

Committee Member

| 2016 Annual Meeting of Stockholders and Proxy Statement

Table of Contents

Proxy Statement Highlights

5

Board Qualifications, Experiences and Backgrounds

The following chart sets forth the varied qualifications, experiences and backgrounds of the Board. See Corporate Governance at Baxter International Inc. Board of Directors Director Qualifications and Director Nominations for additional information.

Creation of two independent boards in connection with the spin-off of Baxalta Incorporated Addition of two new independent directors, Munib Islam and Michael F. Mahoney, to the Board

Appointment of a new Chairman of the Board and CEO, José E. Almeida Approved declassification of the Baxter Board

Adoption of a 3% /3 year / greater of 2 and 20% proxy access Bylaw

investor.baxter.com



Proxy Statement Highlights



Advisory Vote to Approve Named Executive Officer Compensation

What am I voting on?

You are asked to cast a non-binding advisory vote to approve Baxter s compensation programs as described in the Executive Compensation Compensation Discussion & Analysis section of this Proxy Statement.

What is the Board s recommendation?

The Board of Directors recommends a vote FOR this proposal.

The Board and the Compensation Committee believe that Baxter s executive compensation programs appropriately align executives interests with Baxter s strategies and long-term objectives, including the successful completion of the Baxalta Incorporated (Baxalta) spin-off in 2015. See Corporate Developments and Performance Highlights below for additional information regarding certain 2015 highlights.

Where can I find more information?

Concise supporting information is presented below.

See Proposal 2 Advisory Vote to Approved Named Executive Officer Compensation for additional information.

Corporate Developments and Performance Highlights

Development or Highlight
Completion of the Baxalta spin-off

Further Information See page 27

Spin-off permits Baxter management to focus on stand-alone medical products business

Also enables Baxter to more effectively commercialize product offerings and to help drive innovation across the Hospital Products and Renal franchises

Provides flexibility to pursue growth and investment strategies in revenue acceleration, improved profitability and enhanced returns

Based on company estimates, the combined total shareholder return of Baxter and Baxalta totaled approximately 7.5% in 2015, as compared to 1.4% for the S&P 500 Composite Index and 7.0% for the S&P 500 Health Care Index. See Executive Compensation Compensation Discussion and Analysis Summary 2015 Results for additional information

Strong financial results and stockholder return for 2015

See page 27

As discussed below, Baxter had \$10.0 billion of net sales in 2015

Adjusted earnings from continuing operations per diluted share of \$1.38 increased 8% in 2015. See Executive Compensation Compensation Discussion and Analysis Structure of Compensation Program Pay-for-Performance Financial Targets for a reconciliation of adjusted earnings from continuing operations per diluted share to the closest measure determined in accordance with U.S. generally accepted accounting principles (GAAP)

Returned \$910M to stockholders in 2015 through cash dividends, in addition to the value of the shares distributed in the Baxalta spin-off

2015 Global Net Sales

Adjusted Earnings from Continuing Operations per Diluted Share

\$10.0B

Reflects net sales from continuing operations

\$1.38

8% over 2014

| 2016 Annual Meeting of Stockholders and Proxy Statement

Table of Contents

Proxy Statement Highlights



Compensation Design for 2015 and 2016

See page 31

For 2015, long-term compensation consisted of 50% restricted stock units (RSUs) and 50% stock options given the business separation and challenges in establishing appropriate long-term metrics to adequately reflect performance through the spin-off

Cash bonus plan for 2015 was based on adjusted earnings per share (EPS) and adjusted sales, with separate targets established for each half of the year. Targets for first half of 2015 were based on total Baxter results (including Baxalta) and for second half of 2015, solely on Baxter results (after giving effect to the spin-off)

For 2015, Mr. Parkinson s annual base salary, as Chief Executive Officer, totaled \$1,535,000 and he received a cash bonus award of \$3,637,491 and long-term equity incentive awards with a grant date fair value of \$11,466,401

In connection with the appointment of Mr. Almeida as CEO and Chairman in October 2015, Mr. Almeida was awarded an annual base salary of \$1,300,000 and a target annual cash bonus equal to 135% of his salary beginning in 2016 (or \$1,755,000). He also received a long-term equity grant with a grant date fair value of \$7,714,087, consisting of 50% stock options and 50% performance share units (PSUs) as an acceleration of his 2016 annual equity grant

For 2016, cash bonus awards are based on adjusted EPS, adjusted sales and adjusted free cash flow, consistent with the company s increased rigor around the prioritization of capital expenditures

For 2016, equity incentive awards consist of 50% PSUs and 50% stock options for the company s executive officers. 2016 PSU awards are based on three-year growth in shareholder return (GSV) and annual operating margin targets, consistent with the company s increased focus on improving profit margins Stockholder Engagement

See page 29

Baxter sponsors an active stockholder engagement program, with involvement from members of the Board, including the independent lead director (lead director) and members of the Corporate Governance and Compensation Committees

In 2015, the company completed a corporate governance outreach to top investors and covered topics including Board composition and refreshment, succession planning (including the appointment of Mr. José Almeida as the company s Chairman and Chief Executive Officer), Board leadership structure, the company s new proxy access bylaw amendment and Baxter's executive compensation program

investor.baxter.com